Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
Top 5 Myelofibrosis Breakthroughs from EHA 2026 #myelofibrosis | EHA 2026
HealthTreeDescription
Dr. Prithviraj Bose from MD Anderson Cancer Center highlights the five most exciting myelofibrosis advances from EHA 2026.
1. SENTRY TRIAL: Selinexor + Ruxolitinib
First combination to show survival benefit over ruxolitinib alone in the first year of treatment. Higher spleen response rates.
2. AJAX DRUG (AGI-11095): New Type 2 JAK Inhibitor
First-of-its-kind therapy that overcomes resistance to current JAK inhibitors. High spleen and symptom response rates in patients who've already tried other JAK drugs.
3. CALR ANTIBODY (INCA033989): Targets Mutant Calreticulin
Clean safety profile. Improves spleen, symptoms, and anemia. Targets the driver mutation in about 25% of myelofibrosis patients.
4. LUSPATERCEPT (INDEPENDENCE Trial): For Anemia
Already approved for other blood disorders. New phase 3 trial data for myelofibrosis patients who need blood transfusions while on JAK inhibitors.
5. DISC0974: Anti-Hemojuvelin Antibody
New mechanism for treating anemia. Can be used alone or with JAK inhibitors.
Learn more: https://linktr.ee/HealthTreeUniversity
TIMESTAMPS:
0:00 Introduction
0:15 #1: SENTRY Trial - Selinexor + Ruxolitinib
0:32 Why This Survival Benefit Matters
0:58 #2: AJAX Drug (Type 2 JAK Inhibitor)
1:15 How It Overcomes Drug Resistance
1:41 Clinical Results & Future Potential
1:57 #3: CALR Antibody
2:29 How It Works & Who Benefits
2:52 #4: Luspatercept (INDEPENDENCE Trial)
3:06 For Anemia & Transfusion Dependence
3:38 #5: DISC0974 (Anti-Hemojuvelin Antibody)
3:52 New Mechanism for Treating Anemia
4:07 Solo or Combination Treatment
#myelofibrosis #JAK #NewTreatments #EHA2026